Biotech

Vertex Pharmaceuticals

S

Public

Vertex Pharmaceuticals is the world leader in cystic fibrosis (CF) and one of biotech's few large-cap, highly profitable, self-funded innovators. Its CFTR-modulator franchise — anchored by Trikafta/Kaftrio and the next-generation once-daily Alyftrek (vanzacaftor/tezacaftor/deutivacaftor, FDA-approved December 2024) — treats the large majority of the addressable CF population and generated the bulk of $12.0B in FY2025 revenue, with $4.0B of GAAP net income. Vertex is now deploying that cash flow to diversify well beyond CF. It commercialized Casgevy (exagamglogene autotemcel), the first CRISPR/Cas9 gene-editing therapy ever approved, for sickle cell disease and beta thalassemia, partnered with CRISPR Therapeutics. In January 2025 it launched Journavx (suzetrigine), the first genuinely new class of pain medicine in over two decades — an oral, non-opioid NaV1.8 inhibitor. Its pipeline includes zimislecel (VX-880), a stem-cell-derived islet therapy that has rendered type 1 diabetes patients insulin-independent in trials; inaxaplin for APOL1-mediated kidney disease; and povetacicept (from the $4.9B Alpine acquisition) for IgA nephropathy. In July 2026 it agreed to acquire endocrine-disease specialist Crinetics Pharmaceuticals for ~$10B — its largest-ever acquisition — adding the marketed acromegaly drug Palsonify and an endocrinology pipeline. Vertex pushes the envelope by turning single-gene biology into functional cures.

Moderna

A

Public

Moderna is the pioneer and, with BioNTech, one of the two global leaders in messenger-RNA (mRNA) medicine. Founded in 2010 and incubated by Flagship Pioneering, it rose to prominence with Spikevax, its COVID-19 vaccine that reached full FDA approval in 2022 and drove roughly $18B of revenue at its 2022 peak. Moderna is now navigating a steep post-COVID transition: FY2025 revenue fell ~40% to $1.9B and it posted a $2.8B net loss, prompting ~$2.2B of annual cost cuts and a 10% workforce reduction. The company is rebuilding around a broader respiratory franchise — next-gen COVID vaccine mNEXSPIKE, RSV vaccine mRESVIA, and Europe's first flu+COVID combination mCOMBRIAX — while its highest-value bet is intismeran autogene (mRNA-4157/V940), an individualized neoantigen cancer therapy partnered with Merck that has shown durable five-year benefit in melanoma. With ~$7.5B in cash, ~40 development programs, and a targeted return to cash-flow breakeven in 2028, Moderna is a validated-platform leader working through significant near-term financial and execution headwinds.

CRISPR Therapeutics

A

Public

CRISPR Therapeutics is a gene-editing pioneer co-founded in 2013 by Nobel laureate Emmanuelle Charpentier — co-inventor of CRISPR/Cas9 — alongside Rodger Novak and Shaun Foy. Its flagship, Casgevy (exagamglogene autotemcel), is the world's first approved CRISPR/Cas9 gene-editing medicine: a one-time therapy for sickle cell disease and transfusion-dependent beta thalassemia, developed and commercialized with Vertex Pharmaceuticals (which books the sales; CRISPR keeps ~40% of the economics). Casgevy is now approved across 9+ jurisdictions, priced at ~$2.2M per treatment, and in July 2026 the FDA expanded its US label to children as young as two. Commercial uptake has been slower than hoped — constrained by cell-collection bottlenecks — but cumulative patient starts have surpassed 500. Beyond Casgevy, CRISPR is pivoting toward in vivo liver gene editing (cardiovascular programs CTX310 and CTX320), allogeneic CAR-T for autoimmune disease and cancer (zugo-cel/CTX112), and type 1 diabetes. With ~$2.44B in cash and a catalyst-rich 2026 pipeline, it pairs a historic scientific position with a still-nascent commercial ramp.

BioNTech

A

Public

BioNTech is a Mainz-based immunotherapy company that, with Pfizer, co-developed Comirnaty (BNT162b2) — the first authorized mRNA COVID-19 vaccine and one of the best-selling drugs in history. Founded in 2008 by Uğur Şahin and Özlem Türeci (with Christoph Huber) as an individualized cancer-immunotherapy company, BioNTech is now aggressively redeploying its pandemic-era war chest (~€17B in cash) back toward oncology. Its centerpiece is BNT327 (pumitamig), a PD-L1×VEGF-A bispecific antibody obtained through the 2024–25 Biotheus acquisition and co-developed with Bristol Myers Squibb in a partnership worth up to ~$11.1B, now advancing across eight planned Phase 3 trials in lung, breast, gastric and other solid tumors. The pipeline also spans individualized neoantigen mRNA cancer vaccines (autogene cevumeran/BNT122 with Genentech), off-the-shelf cancer vaccines, antibody-drug conjugates, CAR-T and infectious disease. With COVID revenue declining (FY2025 revenue €2.87B against a €1.1B net loss) and heavy R&D spend, BioNTech is a validated-platform leader financing a multi-year bet to become a multi-product oncology company by 2030.